MILFORD, MA--(Marketwired - October 02, 2013) - PLC Systems Inc. (PLCSF), a company focused on innovative medical device technologies, today announced that RenalGuard® was used on a patient following a kidney transplant. The procedure was performed in a hospital in Brazil. This marks the first time the RenalGuard system was used post-kidney transplant and demonstrates one additional potential market for RenalGuard beyond Contrast Induced Acute Kidney Injury (CI-AKI).
Mark R. Tauscher, President and CEO of PLC Systems, stated, "We are pleased that RenalGuard was used to support a patient post-kidney transplant to improve the patient's outcome. Using RenalGuard to accurately manage input and outputs of fluid, allows the healthcare professionals to focus on direct patient care. This case demonstrates RenalGuard's capability in this area, as well as, the potential to expand the use of our RenalGuard therapy as a fluid management system both for CI-AKI and other applications."
Fluid management post-kidney transplant requires accurate fluid balancing to help maintain the function of the new kidney and prevent poor outcomes. RenalGuard's real time fluid management capability helps to monitor and potentially minimize the risk of over- or under-hydration and offers the potential for better outcomes for these patients. RenalGuard is currently being used throughout Europe to reduce the incidence of CI-AKI.
About PLC Systems Inc.
PLC Systems Inc., headquartered in Milford, Mass., is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC's newest product, RenalGuard, has been developed to rapidly remove contrast dyes that are potentially toxic to patients undergoing certain cardiac and vascular imaging procedures. The Product is CE-marked and is being marketed in Europe and selected countries around the world. Two investigator-sponsored European studies have demonstrated RenalGuard's effectiveness at preventing Contrast-Induced Acute Kidney Injury (CI-AKI). RenalGuard is being studied in a pivotal trial in the U.S., as part of the FDA approval process. For more information, visit www.plcmed.com, or connect with the Company on Facebook, Twitter, LinkedIn, YouTube and Google+.
This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if this clinical trial is completed, it may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, the need for additional financing, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2012, a copy of which is on file with the SEC.
PLC Systems, PLC Medical Systems, PLC, RenalGuard and RenalGuard Therapy are trademarks of PLC Systems Inc.